John A. Harre


Business-focused practical solutions provided by a broad-gauged, business savvy lawyer with executive level in-house experience who understands your perspective, pressures and needs.

John Harre concentrates his practice on life sciences, where he assists clients in the negotiation and drafting of licensing agreements and strategic collaborations and advises them on business matters involving intellectual property issues, including mergers and acquisitions, investments and litigation. John primarily works with clients in the biotechnology, pharmaceuticals and medical devices industries, drawing on over 25 years of experience that includes executive in-house counsel and leadership roles and private practice at several top-tier law firms. 

John previously founded an intellectual property and transactional consultancy to advise life sciences companies. He also served as vice president of intellectual property for a Boston-based biopharmaceutical company. While working at a Cambridge, Massachusetts-based biopharmaceutical company for nearly a decade, he had several roles, including vice president, intellectual property, culminating in vice president, general counsel and business development. 


  • UNH Franklin Pierce School of Law, J.D., 1994
  • University of Tennessee, M.S., Biotechnology, 1989
  • University of Missouri, B.A., Biology, 1986

Bar and Court Admissions

  • Massachusetts
  • Texas
  • U.S. Patent & Trademark Office (Agency)


Represents clients in collaborations, licenses, acquisitions and other complex technology transactions with emerging and established pharmaceutical and biotechnology companies and other projects and counsels clients on intellectual property matters, including:

Complex Transactions
  • AffaMed Therapeutics, a global clinical stage biopharmaceutical company, in its strategic collaboration agreement with leading digital therapeutics company Beijing Infinite Brain Technologies to promote the application and development of digital therapy in neurological disorders
  • Yield10, in a Strategic Collaboration Agreement and Exclusive Option Agreement with Rothamsted Research to develop omega-3 oils in Camelina sativa
  • Large biotech in a Research and Exclusive Option Agreement and Asset Purchase Agreement with a biotech start-up
  • New Equilibrium Biosciences, in an Exclusive License Agreement with St. Jude Children’s Research Hospital
  • Intarcia Therapeutics in numerous collaboration and strategic agreements, including:
    • a Strategic Research Collaboration with California Institute for Biomedical Research for the development of stapled-peptide therapeutics
    • a  Strategic Collaboration Agreement with Numab AG for the development of mono- and multi-specific antibodies for the treatment of diabetes, obesity and autoimmune indications
  • Archemix Corp. in numerous collaboration and strategic agreements, including:
    • a $285 million Asset Purchase and License Agreement with Baxter International Inc., Baxter Healthcare Corp., and Baxter Healthcare S.A for Archemix’ Hemophilia and Hemostasis Program
    • a Research Collaboration and Option Agreement with Dicerna Pharmaceuticals, Inc. for the development of aptamer-Dicer Substrate (DsiRNA) therapeutics for the treatment of various diseases
    • a $1.4 billion Research and Development Collaboration, Option and License Agreement with Glaxo Group Ltd. for the development of therapeutics for the treatment of inflammatory diseases
    • a Feasibility Study, License and Option Agreement with Eli Lilly and Company
    • a $245 million Collaborative Research and License Agreement with Takeda Pharmaceutical Company Ltd. for the development of aptamer therapeutics for various diseases 
    • a $580M Collaborative Research and License Agreement with Merck KGaA for the development of aptamer therapeutics for oncology, inflammation and autoimmune diseases
    • a Collaborative Research, Services and License Agreement with Pfizer, Inc. for the development of aptamer therapeutics for various diseases
    • a $680 million Collaborative Research and License Agreement with Elan Pharma International for the development of aptamer therapeutics for various diseases
Intellectual Property
  • Established, built and managed intellectual property function at Archemix Corp. and Intarcia Therapeutics.
  • Developed, implemented and managed global patent filing and prosecution strategies at Archemix Corp. and Intarcia Therapeutics 
  • Secured the issuance of modality (aptamer) wide medical use claims by EPO
  • Developed trademark acquisition strategy and managed trademark portfolio at Intarcia Therapeutics
  • Successfully petitioned for reversal of the rejection of Intarcia Therapeutics’ Proprietary Name Request
  • Lead intellectual property attorney in a multi-patent patent/antitrust suit
*  Mr. Harre handled some of the above representations prior to joining Foley Hoag 

  • Intarcia Therapeutics, Inc., Vice President Intellectual Property
  • Archemix Corp., Vice President, General Counsel and Business Development; Vice President, General Counsel; Vice President, Intellectual Property

Honors & Involvement

  • Member, American Intellectual Property Law Association
  • Member, Dean's Advisory Council, UNH Franklin Pierce School of Law (2018 – present)
  • Co-chair, Legal Working Group, Massachusetts Biotechnology Council (2018– present)